Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated at Stifel Nicolaus

Investment analysts at Stifel Nicolaus assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 84.91% from the company’s current price.

A number of other research analysts also recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Trading Down 0.5 %

Shares of NASDAQ GPCR opened at $27.04 on Wednesday. The company has a 50 day simple moving average of $32.35 and a two-hundred day simple moving average of $36.63. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -36.54 and a beta of -2.78. Structure Therapeutics has a 12 month low of $25.90 and a 12 month high of $62.74.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP grew its stake in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC increased its stake in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares in the last quarter. Driehaus Capital Management LLC raised its position in shares of Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.